Kohler and Guennel Discuss Biomarker Drug Development & New FDA Data Requirements in Regulatory Focus
Precision for Medicine’s Jared Kohler and Tobias Guennel highlight the challenges for researchers pursuing biomarkers and specialty lab data that meet new FDA regulatory standards. (more…)
Jeremy Schafer Comments in Specialty Pharmacy News on Overcoming Costs for Gene Therapy
Jeremy Schafer, director of Precision’s Payer Access Solutions, offers insights into combating the risk and exposures of gene therapy. (more…)
Jeremy Schafer Address Payer Concerns on Dermira’s Acne Treatment in BioPharma
Jeremy Schafer, director of Precision’s Payer Access Solutions, weighs in on the concern of payer coverage for Dermira’s acne topical treatment. (more…)
Digital Biomarkers Becoming Integral to Precision Medicine
In a new commentary for Pharmaceutical Market Europe, Precision for Value’s Austin Speier, VP, Emerging Technology, examines the promise and advantages of integrating digital biomarkers into precision medicine. (more…)
PHE Expert Shafrin: Make Real-World Evidence the New Gold Standard
In an in-depth commentary for Pharmaceutical Market Europe, senior economist Jason Shafrin argues for real-world evidence (RWE) to become the “gold standard” of scientific evidence and heath technology assessments. (more…)